Pokrivcak Tomas, Navratil Jiri, Poprach Alexandr, Stanik Michal, Kiss Igor
Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Case Rep Oncol. 2024 Apr 4;17(1):537-542. doi: 10.1159/000538124. eCollection 2024 Jan-Dec.
Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown.
We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy.
Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.
前列腺癌是男性最常见的癌症之一。尽管发病率急剧上升，但死亡率正在下降。雄激素受体靶向药物（ARTA）制剂是无症状或轻度症状的转移性去势抵抗性前列腺癌（mCRPC）患者的首选治疗方案。恩杂鲁胺用于老年mCRPC患者存在风险，且取决于多种因素。已表明跌倒和骨折风险增加。
我们报告一例老年mCRPC患者使用恩杂鲁胺治疗的病例，该患者具有非常好的长期耐受性和疗效。
尽管患者年龄较大，但由于耐受性良好，无需减少治疗剂量。全剂量使用恩杂鲁胺产生了非常好的治疗效果。
